Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-006-9004-1
Annals of Surgical Oncology 13:1329-1337 (2006)
© 2006 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chau, G.-Y.
Right arrow Articles by Wu, C.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chau, G.-Y.
Right arrow Articles by Wu, C.-W.

Original Article

Postresectional Adjuvant Intraportal Chemotherapy in Patients with Hepatocellular Carcinoma: A Case-Control Study

Gar-Yang Chau, MD, MPH1,2, Wing-Yiu Lui, MD1,2, Shyh-Haw Tsay, MD2,3, Yee Chao, MD, PhD2,4, Kuang-Liang King, MD1,2 and Chew-Wun Wu, MD, FACS1,2

1 Department of Surgery, Taipei Veterans General Hospital, 201 Shih-pai Road, Section 2, Shih-pai, Taipei, Taiwan 112
2 School of Medicine, National Yang-Ming University, 155 Li-Nong Street, Section 2, Peitou, Taipei, Taiwan 112
3 Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan
4 Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan

Correspondence: Address correspondence and reprint requests to: Gar-Yang Chau, MD, MPH; E-mail: gychau{at}vghtpe.gov.tw

Background: The postresectional tumor recurrence rate is high in patients with hepatocellular carcinoma (HCC). Tumor portal venous invasion is the most important factor related to recurrence. Adjuvant intraportal infusion chemotherapy (IPIC) was used in HCC patients to improve the outcomes.

Methods: Between June 1998 and May 1999, 28 HCC patients (IPIC group) underwent postresectional IPIC daily for 2 days with 5-fluorouracil (650 mg/m2), leucovorin (45 mg/m2), doxorubicin (10 mg/m2), and cisplatin (20 mg/m2). Treatment was repeated every 3 weeks for six cycles. Patient outcomes were compared with those of 66 matched HCC patients (control group) who underwent hepatectomy without adjuvant therapy.

Results: The IPIC group received an average of 5.2 cycles of chemotherapy, starting 5 to 24 days after surgery. The most frequent IPIC-related adverse events were upper abdominal pain, vomiting, and myelosuppression. Five-year disease-free and overall survival rates for the IPIC group were 44.6% and 60.7%, respectively. Subgroup analysis of patients with tumor-node-metastasis stage I and II disease identified significantly lower recurrence rates for the IPIC group (33.3%) than the control group (65.0%; P = .025). For patients with stage I and II disease, 5-year disease-free and overall survival rates for the IPIC group (70.6% and 83.3%, respectively) were significantly higher than those of the control group (33.4% and 46.9%, respectively; P < .05). Patients with stage III disease do not benefit from IPIC.

Conclusions: Postoperative IPIC benefits HCC patients with tumor-node-metastasis stage I and II disease. The survival advantages demonstrated justify a selection of patients for future trials.

Key Words: Hepatocellular carcinoma • Hepatic resection • Tumor recurrence • Adjuvant chemotherapy • Intraportal infusion




This article has been cited by other articles:


Home page
 JNMHome page
E. Boucher, G. Bouguen, E. Garin, A. Guillygomarch, K. Boudjema, and J.-L. Raoul
Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up
J. Nucl. Med., March 1, 2008; 49(3): 362 - 366.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of Surgical Oncology.